Cargando…

Benefit-risk balance of COVID drugs. New prospects

Detalles Bibliográficos
Autores principales:	Cracowski, Jean-Luc, Richard, Vincent, Molimard, Mathieu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444335/ https://www.ncbi.nlm.nih.gov/pubmed/36100496 http://dx.doi.org/10.1016/j.therap.2022.09.001

Ejemplares similares

Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic
por: Cracowski, Jean-Luc, et al.
Publicado: (2020)

COVID-19: Pharmacology has kept the science ship running during the storm
por: Molimard, Mathieu, et al.
Publicado: (2021)

DPP-4 inhibitors and severe course of illness in patients with COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2021)

Drugs acting on renin angiotensin system and use in ill patients with COVID-19
por: Alexandre, Joachim, et al.
Publicado: (2020)

Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
por: Reid, David M.
Publicado: (2020)

Balancing risk and benefit during coronavirus
por: Sehn, Laurie H.
Publicado: (2020)

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit
por: Ewer, Michael S, et al.
Publicado: (2016)

Balancing risks and benefits of artificial intelligence in the health sector
por: Goodman, Kenneth, et al.
Publicado: (2020)

Neurosurgical innovation: balancing the risks and benefits of technical novelty
por: Cohen-Gadol, Aaron A.
Publicado: (2019)

Renin-angiotensin-aldosterone system and COVID-19 infection
por: Alexandre, Joachim, et al.
Publicado: (2020)

Balancing gastrointestinal benefit–risk in individuals who are prescribed NSAIDs for arthritis
por: Bijlsma, Johannes W. J.
Publicado: (2010)

Balancing Benefits and Risks: Do Inhaled Corticosteroids Modify the Lung Microbiome?
por: Singh, Shivani, et al.
Publicado: (2021)

Adverse event reporting and Bell's palsy risk after COVID-19 vaccination
por: Khouri, Charles, et al.
Publicado: (2021)

Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits
por: Lué, Alberto, et al.
Publicado: (2016)

Drug trials: Risk, benefit analysis
por: Damle, S. G.
Publicado: (2011)

Diabetes and COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2020)

Diabète et COVID-19
por: Bouhanick, Béatrice, et al.
Publicado: (2020)

Balancing the benefits and harms of radiotherapy post-radical prostatectomy
por: Lamb, Benjamin W., et al.
Publicado: (2018)

Understanding the variability of pharmaco‐epidemiological studies assessing the risk of appendicitis with mRNA COVID‐19 vaccines
por: Jambon‐Barbara, Clement, et al.
Publicado: (2022)

Balancing the Risks and Benefits of Long‐Term Antiplatelet Therapies for Cardiovascular Disease: Clinical, Research, and Regulatory Implications
por: Alfredsson, Joakim, et al.
Publicado: (2015)

Advances in cancer therapy: clinical benefit of new cancer drugs
por: Michaeli, Daniel Tobias, et al.
Publicado: (2023)

Intra-procedural anticoagulation protocols for left-sided cardiac ablations: Striking a balance between risk and benefit
por: Siontis, Konstantinos C.
Publicado: (2016)

Artificial Intelligence for Personalized Genetics and New Drug Development: Benefits and Cautions
por: Gallo, Crescenzio
Publicado: (2023)

Prevention of risks associated with inappropriate use/unnecessary consumption of medicines()
por: Cracowski, Jean-Luc, et al.
Publicado: (2022)

Benefit-to-risk balance of bronchoalveolar lavage in the critically ill. A prospective, multicenter cohort study
por: Kamel, Toufik, et al.
Publicado: (2020)

The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
por: Goldberg, Richard M., et al.
Publicado: (2017)

Reassessing the risks and benefits of COVID-19 precautions in 2023
por: Ollila, Thomas A., et al.
Publicado: (2023)

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis
por: Hlavaty, Alex, et al.
Publicado: (2022)

Carditis following COVID-19 vaccination: balancing the risks and benefits
por: Ling, Ryan Ruiyang, et al.
Publicado: (2023)

Balancing benefits and risks in the era of biologics
por: Adami, Giovanni, et al.
Publicado: (2019)

Non-steroidal anti-inflammatory drugs and their benefits and harms: the challenge of interpreting meta-analyses and observational data sets when balanced data are not analyzed and reported
por: Simon, Lee S.
Publicado: (2015)

Benefits and risks of sugammadex
por: Park, Jong-Yeon
Publicado: (2015)

Nanocosmetics: benefits and risks
por: Shokri, Javad
Publicado: (2017)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review
por: Grange, Lucile, et al.
Publicado: (2020)

Confusing Inequitable Medicare Prescription Drug Benefit
por: Shearer, Gail E.
Publicado: (2007)

Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children
por: Yang, Chengliang, et al.
Publicado: (2021)

“Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients
por: Rokkam, Venkata Ram Pradeep, et al.
Publicado: (2020)

Procedural Volumes in the Era of COVID: The Risk Versus Benefit Trade-Off
por: Khandkar, Chinmay, et al.
Publicado: (2021)

Moonshot Science—Risks and Benefits
por: Casadevall, Arturo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h51hqv62t3lph7rnki61qm4rkj